Tofacitinib for celiac disease and microscopic colitis: killing two birds with one stone
|Journal||Volume 86 - 2023|
|Issue||Fasc.2 - Case reports|
|Author(s)||M. Lenfant 1 2, G. De Hertogh 3, B. Verstockt 1 2|
VIEW FREE PDF
(1) Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium
(2) Translational Research in Gastrointestinal Disorders, Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, Leuven, Belgium
(3) Department of Pathology, University Hospitals Leuven, Leuven, Belgium
Microscopic colitis is a chronic inflammatory condition of the colon. Firstline treatment consists of budesonide, with the consideration of biological agents in refractory cases. Celiac disease is a chronic immune mediated and gluten-induced enteropathy, with treatment consisting of a gluten-free diet. There is an association between microscopic colitis and instead of xand celiac disease, especially in refractory cases they can coincide. In this manuscript, we report for the first time the efficacy of tofacitinib, a pan Janus kinase inhibitor, in the treatment of concomitant microscopic colitis and celiac disease, resulting in persistent clinical and histological remission.
Keywords: janus kinase inhibitor, celiac disease, microscopic colitis, tofacitinib.
© Acta Gastro-Enterologica Belgica.